Notice & Service
In March 2015, Jeon’s Lab was founded for the first time at Hallym
University College of Medicine for various in-depth research projects
and studies for intracranial hemorrhage, subarachnoid hemorrhage,
acute cerebral infarct, and traumatic brain injury. To date on March
2022, we have published a total of 81 papers as the first or corresponding
authors in reputable international journals and achieved 22 patent
registrations. At the same time, based on our research results, we are
providing personalized genome analysis services for several brain
diseases such as cerebrovascular, neurodegenerative, and neurotrauma,
and are implementing advanced medical care in Gangwon-do, a
neglected area in the Republic of Korea. However, a lot has to be done
for Jeon’s Lab to achieve satisfactory research results. Currently,
there are efforts to find new biomarkers related to the occurrence
- Principal Inverstigator
- Jin Pyeong Jeon MD. Ph.D.
- Department of Neurosurgery,
Hallym University College of
Republic of Korea
of various strokes in Koreans through various genome analyses using large-scale genomic big data of the domestic and foreign country. We are expanding into various bioinformatics research such as epigenetic research, single-cell analysis, and artificial intelligence, while simultaneously developing a treatment for stroke using stem cells, nanomaterials, and vagus nerve stimulation, and advocating for healthy food to maintain a healthy brain. In addition, we are doing our best to educate the next generation of scholars who specialize in stroke. Jeon’s Lab is actively engaging in domestic and international exchanges based on the technology and experience it has accumulated so far and will ensure continuous leaps and bounds. I would like to express my gratitude to the Hallym University Medical Center, the head of the Neurosurgery Department, the director of Chuncheon Sacred Heart Hospital, and many people who donated towards the research.
In March 2015, JEON LAB was founded for the first time at Hallym
University College of Medicine for genome-based intracranial hemor-
rhage (ICH), cerebral hemorrhage, and traumatic brain injury. As a
result of our efforts to enhance the genome research capability re-
quired for precision medicine, we have published a total of 81 papers
as the lead author/corresponding author in international journals
over the past 7 years and achieved 22 patent registrations. At the
same time, based on our research results, hospitals are providing
genome analysis services for cerebrovascular, neurodegenerative,
and neurotrauma diseases including ICH in the daily clinics, and are
implementing advanced medical care in Gangwon-do, a relatively
medically neglected area in Korea. Jeon Lab is not satisfied with the
present but is looking for new biomarkers related to the occurrence of ICH in Koreans through various genome analysis using large-scale genomic big data of domestic and foreign country. We are currently expanding into various bioinformatics research such as epigenetic research, single cell analysis, and artificial intelligence, while simultaneously developing a treatment for ICH using stem cells, nanomaterials, and vagus nerve stimulation, and health food to protect brain health. In addition, we are doing our best to educate the next generation of scholars who specialize in ICH. JEON LAB is actively engaging in domestic and international exchanges based on the technology and experience it has accumulated so far and will do its best to make continuous leaps and bounds. I would like to express my gratitude to the Hallym University Medical Center, the head of Neurosurgery Department, the director of Chuncheon Sacred Heart Hospital, and many people who donated for the research.
Jong Tae Kim, Ph.D.
Dr. Jong-Tae Kim is a senior researcher in the Institute of New Frontier Research Team at Hallym University.
He analyzed the possibilities of treatment using various adult stem cells. He has conducted a pre-clinical study
on heart failure therapy using cardiac stem cells and on spinal cord injury therapy using peripheral nerve-derived
neural stem cells. Currently, he is studying the development of cerebral organoids for therapeutics in brain injury
using pluripotent stem cells.
Eun Pyo Hong, Ph.D.
Data Management in Chief
Dr. Eunpyo Hong is a senior scientist in the Institute of New Frontier Research at the Hallym University and was
a research Fellow at Harvard Medical School and Broad Institute between 2018 and 2021, respectively, in Boston,
MA USA. He is a professional in Genetic Epidemiology and Bioinformatics/Biostatistics. He conducted research
to identify genetic modifications and their mechanisms while evaluating the risk of developing cardio- and
Chan Hum Park, Ph.D.
Dr. Chan Hum Park has been working with the Institute of New Frontier Research Team as a senior researcher.
He has studied traditional Korean medicine and pharmaceutical sciences. “My dream is to help improve human
health. To realize my dream, I have been developing functional foods and pharmaceutical materials to date.
Besides, I'm a team player. I'm happy to collaborate with other people on any research projects”.
Dong Hyuk Youn, Ph.D.
Dong Hyuk Youn is a research fellow at the Institute of New Frontier Research at Hallym University.
He has trained in surgery guidance for neurosurgical rodent models of various cerebrovascular diseases
and traumatic brain injuries. He is currently working to develop a treatment for hemorrhage stroke with a
focus on mitochondria and nanomaterial.
Sung Woo Han, MSc.
Sung Woo Han is a master’s student in the Institute of New Frontier Research Team at Hallym University.
He has conducted a research study on the haptoglobin phenotype as a predictor of cerebrovascular diseases.
Also, he has training in various techniques for various in vivo and in vitro studies.
Seung Hyuk Lim, MSc.
Seung Hyuk Lim is a master’s student at the Institute of New Frontier Research Team at Hallym University.
He has been researching the mechanisms of secondary brain injury in traumatic brain injury and ischemic
stroke rodent models, and developing therapeutic agents to alleviate brain swelling after ictus. He is also
interested in the brain-organ axis and is studying the relationship between them.
Tae Yeon Kim, MSc.
Tae-yeon Kim graduated a major in Biomedical Science from Hallym University.
Currently, she is pursuing a master’s program in medical science at Hallym University.
She is participating in research on the functional effects of stem cell transplantation in traumatic brain injury
and hemorrhage stroke rodent models.
Bong Jun Kim, Ph.D.
Dr. Bong Jun Kim am a Ph.D. researcher in the Institute of New Frontier Research, Hallym University,
Chuncheon, South Korea. He performs bioinformatics analysis (in silico), animal testing (in vivo), and basic
science experiments (in vitro).
Prof. Hyojong Yoo, Ph.D.
Hyojong Yoo is currently a Professor at the Department of Materials Science and Chemical Engineering,
Hanyang University, Ansan, city, Gyeonggi-do, South Korea. He received his B.S. from Yonsei University and M.S.
from Seoul National University in Chemistry. He earned his Ph.D. from the University of Pennsylvania (2006)
in Inorganic and Materials Chemistry. His current research focus is on the synthesis and massive application of
functional nanohybrid materials which involves designing and preparation of highly applicable inorganic
nanocomposites, coordinating polymer-based nanohybrids, metallosupramolecules, silicon materials, and
improvement of characterization and analysis techniques. The developed materials are employed in
energy technology, sensor, catalysis, and medical application.
Seung Chan Lee, Ph.D.
Seungchan Lee has received an M.S. and Ph.D. degree in electrical engineering and computer science from
the Gwangju Institute of Science and Technology, Gwangju, South Korea, in 2012 and 2020, respectively.
He is now a researcher with the IT Convergence Component Research Center, Korea Electronics Technology
Institute at Gwangju. His current research interests include the development of biomedical sensor and
stimulation systems such as EEG/fNIRS brain monitoring systems and Vagus nerve stimulation.
Harry Jung, Ph.D.
Harry Jung is a junior scientist at the Institute of New Frontier Research at Hallym University.
She has trained in the development of functional food and therapeutic drugs for metabolic disorders and
cerebrovascular diseases in rodent models. She is currently investigating their therapeutic effects on bone
marrow mesenchymal stem cells (MSCs) and MSCs derived exosomes in subarachnoid hemorrhage.